Immunological assay selection: essential preparation steps

Immunological assay selection: essential preparation steps for pediatric diagnostic panels

In a 10-year Massachusetts newborn-screening program covering 720,038 infants from February 2009 to January 2019, real-time PCR quantification of T-cell receptor excision circles (TRECs) flagged 237 newborns—about 0.03% of the screened cohort—for further immunological evaluation. The reported incidence of severe combined immunodeficiency (SCID) and leaky SCID was approximately 1 in 80,000 live births.

Those figures describe the flow of patients through a screening pathway: how many newborns were referred and how often confirmed disease occurred. They do not, by themselves, establish assay specificity or analytical sensitivity. A low referral rate may reflect the chosen cutoff, the characteristics of the screened population, and the structure of the follow-up algorithm. It also says nothing about whether every affected infant will be detected or how reliably a particular confirmatory assay performs in a local laboratory.

That distinction is central to immunological assay selection for pediatric diagnostic panels. The question is not simply whether a test can produce a number. The laboratory must be able to interpret that number for a particular age, specimen type, clinical phenotype, and stage of investigation. In children, developmental biology and specimen logistics are not background details. They are part of the test.

Navigating Developmental Dynamics in Pediatric Reference Ranges

Pediatric immune measurements do not settle into a single adult pattern. Absolute lymphocyte counts, T-cell subsets, B-cell numbers, natural killer cell populations, serum immunoglobulins, and the balance between naïve and memory lymphocytes all change during infancy, childhood, and adolescence.

The effect is especially pronounced early in life. An infant may have an absolute lymphocyte count that would look unusually high in an adult but is expected for that developmental stage. Conversely, a child with a clinically important reduction in a lymphocyte subset may still fall within a broad adult interval and be incorrectly reassured. The same numerical result can therefore carry different clinical meanings at different ages.

A pediatric panel should account for at least the following variables:

• Age at collection. Reference intervals need to be matched to the child’s exact age or to a clearly defined age band. The useful granularity is greatest during infancy and the first years of life, when immune-cell populations change quickly.
• Absolute counts and percentages. A percentage alone can be misleading. A normal proportion of CD4+ cells does not exclude an abnormal absolute CD4+ count if the total lymphocyte count is low.
• The complete blood count. A CBC with automated differential provides the denominator needed to interpret many flow-cytometry results and helps identify broader cytopenias or leukocyte abnormalities.
• Cellular phenotype. CD3+ T cells, CD4+ and CD8+ subsets, CD19+ B cells, and CD16+/CD56+ natural killer cells answer different clinical questions. Naïve and memory markers, commonly assessed with CD45RA and CD45RO, add context when T-cell maturation or thymic output is in question.
• Immunoglobulin class and subclass. IgG, IgA, IgM, and, where clinically justified, IgG subclasses should be interpreted against age-specific intervals rather than adult laboratory limits.
• Clinical context. Prematurity, recent infection, nutritional status, medications, transfusion history, and treatment with immunoglobulin can all affect interpretation.

The physiology of immunoglobulins also needs to be described accurately. Maternal IgG is transferred across the placenta before birth, with the amount varying by gestational age and other maternal and fetal factors. After birth, passively acquired maternal IgG declines over time while the infant’s own production develops. This creates a period in which a low or changing IgG concentration may reflect normal maturation, disease, or both. IgA production also matures gradually and may remain below adult concentrations through childhood; adult-like values should not be assumed in a young child.

The laboratory report should make these distinctions visible instead of leaving them to the reader. A technically correct value paired with an inappropriate adult interval is still clinically unsafe.

In pediatric immunology, the reference range is part of the result. An out-of-range flag without an age-matched comparator is not a diagnosis.

Age-specific intervals are not interchangeable across laboratories without qualification. They may differ because of population characteristics, instrument configuration, antibody clones, statistical methods, and whether the laboratory reports central intervals or broader percentile-based limits. For children being evaluated for an inborn error of immunity, the report should identify the reference population and the units used for both percentages and absolute counts.

A sensible preparation step is to define the interpretation framework before ordering the panel. If the clinical question concerns severe T-cell lymphopenia, the laboratory may need absolute T-cell counts and naïve-cell assessment. If recurrent bacterial infections dominate the presentation, quantitative immunoglobulins and B-cell evaluation may be more informative. If unusual mycobacterial or fungal infections are present, the workup may need to extend toward phagocyte, complement, or functional cellular assays. A single broad panel is not automatically the most rational first panel.

Standardizing Flow Cytometry: The EuroFlow PIDOT Approach

Flow cytometric immunophenotyping remains a central tool in pediatric immune evaluation. It can quantify major lymphocyte populations and, when appropriately designed, show whether a child has a pattern suggestive of T-cell, B-cell, or combined immune deficiency.

The difficulty is that flow cytometry is not one universal method. Results are affected by antibody clones, fluorochrome combinations, instrument configuration, compensation, sample age, gating strategy, and the reference population used for interpretation. Two laboratories can examine similar specimens and produce reports that are difficult to compare if their panels and definitions differ substantially.

The EuroFlow Primary Immunodeficiency Orientation Tube, or PIDOT, was developed to support greater standardization. The approach uses a defined multicolor orientation panel and additional classification tubes for more detailed assessment of lymphoid populations. Its value lies in harmonized marker selection, instrument and analysis procedures, and a common framework for reporting—not in eliminating the need for local laboratory work.

A standardized architecture can make implementation more reproducible, but each laboratory still has to verify that the method performs acceptably on its own instruments, reagents, specimen types, and patient population. Local verification and, where applicable, validation remain necessary. The laboratory must establish that it can resolve the relevant populations, maintain acceptable staining and analysis quality, and interpret results against suitable pediatric reference data.

For a laboratory starting pediatric flow work, adopting a published standardized framework can reduce unnecessary design choices and improve communication with referral centers. It does not remove the local burden of instrument verification, reagent qualification, quality control, staff training, or reference-range assessment.

The practical question is therefore not whether a center has copied a recognized panel. It is whether the center can demonstrate stable performance for the populations it intends to report. That includes low-frequency populations, age-dependent subsets, and specimens whose quality is compromised by transport delay or limited volume.

Panel selection should follow the clinical question. A basic orientation panel may be appropriate for an initial evaluation of suspected lymphopenia. More detailed tubes may be needed for suspected agammaglobulinemia, combined immunodeficiency, defects of T-cell maturation, or disorders involving unusual lymphocyte phenotypes. The laboratory should also define in advance when a result will trigger reflex testing rather than expanding every specimen into the most extensive available panel.

Optimizing Sample Collection and Pre-Analytical Integrity

Pediatric blood collection is often the first point at which an otherwise well-designed diagnostic pathway becomes unreliable. Small specimen volumes, difficult venipuncture, transport delays, recent transfusion, and limited access to repeat sampling all matter. Pre-analytical requirements must therefore be written separately for each method.

For flow cytometry, whole blood is commonly collected in an EDTA tube. The exact volume depends on the number of tubes, the laboratory’s validated procedure, the child’s blood volume, and whether a CBC is required from the same collection. A laboratory may specify approximately 2 mL for its standard pediatric workflow, but that volume should not be presented as a universal rule for every panel or age group. In very small infants, the minimum acceptable volume may need to be negotiated with the laboratory before collection.

Flow-cytometry requirements generally include:

1. Correct anticoagulant and tube fill. EDTA is commonly used for immunophenotyping, but the laboratory’s validated tube type and collection instructions should be followed. Underfilled or clotted specimens may be unsuitable.

2. Prompt transport. Many laboratories request analysis as soon as possible after collection because cell viability and antigen expression can change during storage. A 24-hour window may be appropriate for a particular validated flow protocol, but it is not a universal guarantee of specimen stability.

3. Temperature control. Flow samples are often transported at controlled room temperature rather than refrigerated. Cold exposure can alter cell morphology, scatter properties, and the behavior of some leukocyte populations. The laboratory’s transport range should be followed rather than inferred from general blood-sample practice.

4. Paired CBC with differential. Absolute subset counts require an appropriate leukocyte and lymphocyte denominator. Percentages without corresponding absolute counts are incomplete for many pediatric diagnostic questions.

5. Clinical and treatment information. Recent transfusion, corticosteroids, immunosuppressive therapy, intravenous immunoglobulin, acute infection, and prior hematopoietic-cell treatment can affect interpretation.

The handling requirements for genetic testing are different. DNA-based tests may use EDTA blood, but the acceptable volume, transport temperature, stability period, and DNA extraction requirements depend on the laboratory and the method. A specimen suitable for sequencing is not automatically suitable for same-day flow cytometry, and a delay that is unacceptable for viable-cell analysis may be tolerable for DNA extraction.

For genetic testing, the ordering team should clarify:

• whether peripheral blood is the preferred specimen or whether another source is indicated;
• the minimum blood volume for the child’s age;
• whether the sample must arrive within a defined period;
• whether refrigeration, ambient transport, or another condition is required;
• whether a second sample or parental samples may be needed for variant interpretation;
• whether recent transfusion could introduce donor DNA and affect the result;
• how the laboratory handles insufficient DNA, poor sequencing quality, copy-number analysis, or repeat collection.

These instructions should not be collapsed into one generic rule such as EDTA blood at room temperature with a 24-hour processing window. That type of statement may be reasonable for a specific flow-cytometry protocol, but it cannot be extended automatically to genetic testing performed on peripheral blood.

The specimen requirement belongs to the method. Flow cytometry needs viable, interpretable cells; genetic testing needs suitable nucleic acid. One tube can support both workflows only when both laboratories have confirmed that it does.

Pre-analytical failures are not always obvious. A report may be technically issued even when the specimen was delayed, partially clotted, inadequately filled, or collected after an intervention that changes the result. The laboratory should have criteria for rejecting a sample, qualifying a result, or recommending repeat collection. In a child with a high-risk phenotype, a qualified or incomplete result should not be treated as evidence that the immune system is normal.

Integrating TREC Assays and Genetic Panels in Diagnostic Workflows

TREC testing and definitive immune-deficiency diagnosis occupy different positions in the clinical pathway. A TREC assay measures circular DNA products generated during T-cell receptor gene rearrangement and is commonly used on dried blood spots for newborn screening. TREC levels provide an indirect signal of recent thymic output and can identify newborns who may have severe or clinically important T-cell lymphopenia.

A reduced or absent TREC result is a triage signal, not a diagnosis of SCID. Low values can be associated with SCID and other conditions affecting T-cell production, but they may also lead to evaluation for non-SCID causes of T-cell lymphopenia. The screening cutoff, assay design, reference gene, specimen quality, and local follow-up algorithm all influence how results are handled.

An abnormal screen generally requires timely clinical follow-up that may include:

• repeat or confirmatory testing according to the newborn-screening protocol;
• flow-cytometric enumeration of T, B, and NK cells;
• assessment of naïve and memory T-cell populations when clinically indicated;
• quantitative immunoglobulins interpreted against age-specific intervals;
• review of infection history, growth, physical findings, family history, and transfusion status;
• genetic testing when the cellular phenotype and clinical presentation support an inborn error of immunity.

The order and extent of testing should be adapted to the child. A newborn with a profoundly abnormal screen and very low T-cell numbers requires a different level of urgency from an older child with recurrent infections and a normal TREC history. Conversely, a normal TREC screen does not exclude every immune disorder. It is not designed to detect all antibody deficiencies, complement disorders, phagocyte defects, or every form of combined immunodeficiency.

Genetic testing can be organized in tiers, but the boundaries are not rigid. A targeted panel may be efficient when the phenotype strongly suggests a particular group of genes. Broader sequencing becomes more useful when the phenotype is atypical, several pathways are plausible, or initial testing is unrevealing.

• Targeted panels examine a curated set of genes associated with the suspected phenotype. They can provide efficient coverage of relevant genes and may simplify interpretation, but they can miss a disease-causing gene outside the selected set or variants that the assay is not designed to detect.
• Broader disease-focused panels expand gene coverage while retaining an immune-deficiency-oriented interpretation framework. Their usefulness depends on the quality of the gene list, coverage of relevant regions, and ability to detect copy-number or structural variants.
• Whole-exome sequencing examines coding regions across a much broader set of genes. It may be valuable in atypical or unresolved cases, but it creates a larger interpretation burden and can identify variants of uncertain significance or incidental findings.
• Whole-genome sequencing may offer broader detection of some noncoding and structural changes, where available, but it still requires careful phenotype correlation and laboratory-specific validation.

The commonly discussed SCID-associated genes—including IL2RG, JAK3, RAG1, RAG2, ADA, DCLRE1C, and LIG4—illustrate why the clinical phenotype matters. The same laboratory finding can arise from different molecular mechanisms, and the absence of a variant in a limited panel does not exclude an immune disorder.

Genetic results also require restraint. A pathogenic variant that fits the phenotype can substantially clarify diagnosis and management. A variant of uncertain significance does not establish disease by itself. Similarly, a negative panel does not prove normal immune function, especially when the assay does not cover all relevant variant types or when the suspected disorder remains poorly defined.

A low TREC result should therefore lead to confirmation, not to an automatic diagnostic label or treatment decision. Decisions about infection precautions, vaccination, prophylaxis, or transplantation must be made from the integrated clinical, cellular, functional, and genetic picture.

Clinical Safety Protocols: Managing Vaccination Risks During Evaluation

Vaccination history is part of the immunology workup, not an administrative footnote. Some live-attenuated vaccines can pose a serious risk to children with significant T-cell or other immune defects. The relevant vaccines vary by country and schedule, but may include rotavirus, measles-mumps-rubella, varicella, and BCG in regions where BCG is routinely used.

When severe immunodeficiency is suspected, the clinical team should review upcoming vaccines before the next dose is given. The decision to defer a live vaccine should be made by the responsible clinician using the child’s presentation, screening result, preliminary laboratory findings, and local immunization guidance. It should not be framed as a blanket rule that every abnormal screening result permanently prohibits vaccination.

Useful operational steps include:

• recording the child’s complete vaccination history when the immunology workup is ordered;
• identifying any live-attenuated vaccine already administered and documenting the date;
• checking whether a dose is scheduled before confirmatory testing can be completed;
• communicating promptly with the primary-care and immunization teams;
• arranging urgent confirmatory testing when the screening result or clinical picture suggests a substantial risk;
• documenting who is responsible for reassessing vaccine eligibility after the initial results return.

An abnormal TREC result is not vaccine clearance. It initiates a pathway in which the risk of vaccination is weighed against the risk of delaying protection. The child may also have a condition that affects the safety or effectiveness of non-live vaccines, and immunoglobulin replacement therapy can complicate the interpretation of some antibody measurements. These issues should be addressed in the same clinical plan rather than treated as separate paperwork.

The safety concern is greatest when there is evidence of severe T-cell dysfunction, but clinical caution should not depend on a single laboratory number. A child with recurrent opportunistic infections, persistent lymphopenia, failure to thrive, a family history of early unexplained deaths, or a concerning physical phenotype may need urgent evaluation even when the newborn-screening history is unavailable or normal.

Live-attenuated vaccine decisions belong inside the diagnostic pathway. Screening can trigger caution, but only the integrated clinical assessment can establish whether vaccination is appropriate.

Clinical Utility Assessment

A practical diagnostic architecture for pediatric immunology is layered rather than linear. Each layer answers a different question and has its own specimen, timing, and interpretation requirements.

1. Screening: TREC testing on a newborn-screening specimen identifies infants who may have reduced thymic output or significant T-cell lymphopenia.

2. Cellular confirmation: Flow cytometry measures T-, B-, and NK-cell populations and, when indicated, naïve and memory T-cell subsets. Results must be interpreted with a paired CBC and age-appropriate reference intervals.

3. Humoral assessment: Quantitative immunoglobulins and selected functional antibody studies evaluate the humoral component when the age and clinical history make those measurements meaningful.

4. Functional testing: Additional assays may be needed for lymphocyte proliferation, oxidative burst, complement activity, or other immune pathways that are not captured by a basic immunophenotyping panel.

5. Molecular clarification: Targeted or broader genetic testing investigates the cause when the phenotype and laboratory findings support an inborn error of immunity.

This structure also clarifies what each test cannot do. TREC screening is not a complete screen for all primary immunodeficiencies. Flow cytometry can show abnormal cell numbers or phenotypes, but it does not by itself establish normal immune function. Immunoglobulin concentrations do not fully measure antibody quality. Genetic sequencing can identify a likely cause, but it does not make a variant clinically meaningful without phenotype correlation.

The pre-analytical rules must remain method-specific. A flow-cytometry specimen may require prompt ambient-temperature transport and analysis within a locally validated interval. A genetic test may use EDTA blood under a different stability and transport protocol. If both tests are being considered, the collection team should confirm the requirements with both laboratories before drawing the child.

Standardization is valuable, but it is not a substitute for local competence. A PIDOT-based flow approach can improve consistency across sites, yet the laboratory must still verify the method. Age-matched reference intervals, quality controls, staff training, instrument performance, and reporting conventions remain local responsibilities.

The final limitation is conceptual. No single assay rules out every disorder affecting cellular immunity, humoral immunity, complement, or phagocyte function. A well-designed panel is not the same thing as a complete evaluation. The strongest diagnostic workflow is the one that matches the test to the biological question, keeps specimen handling under control, and treats unexpected results as reasons to reassess rather than as permission to stop investigating.